NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-021-2015-0-CN-34 Anti-CD70 Chimeric Antigen Receptors CN DIV 202111253336.5 Pending
NCI E-028-2015-1-CN-41 Anti-Mutated Kras T Cell Receptors CN DIV 202111263859.8 Pending
NCI E-253-2020-0-PCT-02 SINGLE DOMAIN ANTIBODIES TARGETING SARS CORONAVIRUS SPIKE PROTEIN AND USES THEREOF PCT PCT PCT/US2021/056548 Expired
NCI E-240-2015-1-CN-09 Methods of Analyzing Virus-Derived Therapeutics CN DIV 202111246733X Abandoned
NCI E-132-2012-0-US-12 ALTERING THE IMMUNDOMINANCE HIERARCHY USING A DNA VACCINE EXPRESSING CONSERVED REGIONS US CON 17/511,499 Abandoned
NCATS E-060-2019-0-US-03 A Highly Efficient Nociceptor Differentiation Protocol For Human Pluripotent Stem Cells US National Stage 17/605,876 Pending
NIAID E-052-2017-4-NZ-86 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection NZ DIV 781602 Pending
NEI E-162-2016-0-JP-32 GENE THERAPY FOR RETINITIS PIGMENTOSA JP DIV 2021-172128 Issued
NIAID E-220-2020-0-PCT-02 ANTIBODIES THAT NEUTRALIZE TYPE-I INTERFERON (IFN) ACTIVITY PCT PCT PCT/US2021/056067 Expired
NIAID E-133-2015-0-EP-10 NEUTRALIZING ANTIBODIES TO HIV-1 GP41 AND THEIR USE EP DIV 21204045.5 Pending
NINDS E-102-2019-1-EP-04 HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC RESONANCE IMAGING OF CORTICAL LESIONS EP National Stage 20726999.4 Pending
NCATS E-060-2019-0-CA-04 A Highly Efficient Nociceptor Differentiation Protocol For Human Pluripotent Stem Cells CA National Stage 3137838 Pending
NIAID E-066-2014-0-US-10 STABILIZED INFLUENZA HEMAGGLUTININ STEM REGION TRIMERS AND USES THEREOF US DIV 17/504,002 11679151 Issued PDF
NIAID E-004-2022-0-PCT-02 Compositions and Methods of Manufacturing Amphiphlic Block Copolymers that Form Nanoparticles in Situ PCT PCT PCT/US2021/055414 Expired
NIAID E-004-2022-0-US-02 Compositions and Methods of Manufacturing Amphiphlic Block Copolymers that Form Nanoparticles in Situ US National Stage 18/032,538 Pending
NIAID E-004-2022-0-CA-01 Compositions and Methods of Manufacturing Amphiphlic Block Copolymers that Form Nanoparticles in Situ CA National Stage 3195623 Pending
NIAID E-203-2020-0-US-04 Star Co-polymers For Ligand Display And Small Molecule Drug Delivery US National Stage 17/604,227 Pending
NIAID E-178-2019-1-PCT-01 STABILIZED NOROVIRUS VIRUS-LIKE PARTICLES AS VACCINE IMMUNOGENS PCT PCT COMB PCT/US2021/055018 Expired
NHGRI E-147-2020-0-PCT-03 HIGH CONCENTRATION METHYLCOBALAMIN OR COMBINATION OF METHYL- AND HYDROXOCOBALAMIN FOR THE TREATMENT OF COBALAMIN C DEFICIENCY AND RELATED DISORDERS PCT PCT PCT/US2021/054619 Expired
NCI E-495-2013-0-JP-23 Anti-Human Papillomavirus 16 E6 T Cell Receptors JP DIV 2021-166407 Issued
NIBIB E-007-2021-0-PCT-02 ANTIBODY SPECIFIC FOR SARS]COV]2 RECEPTOR BINDING DOMAIN AND THERAPEUTIC METHODS PCT PCT PCT/US2021/054281 Expired
NIDA E-077-2019-0-US-06 D3 RECEPTOR AGONIST COMPOUNDS; METHODS OF PREPARATION; INTERMEDIATES THEREOF; AND METHODS OF USE THEREOF US National Stage 17/602,504 Pending
NCI E-495-2013-0-JP-01 Anti-Human Papillomavirus 16 E6 T Cell Receptors JP DIV
NCI E-065-2019-0-US-03 HYBRID NUCLEIC ACID SWITCHES US National Stage 17/602,204 Pending
NCATS E-120-2018-0-US-02 REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS US National Stage 17/594,086 Pending
NCATS E-179-2018-0-US-02 REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA US National Stage 17/594,090 Pending
NCI E-264-2011-0-AU-12 Delivery Of Packaged RNA To Mammalian Cells AU DIV 2021240286 Pending
NCI E-189-2020-1-PCT-01 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION PCT PCT COMB PCT/US2021/053060 Expired
NCI E-189-2020-1-TW-02 HLA CLASS II-RESTRICTED DQ T CELL RECEPTORS AGAINST RAS WITH G13D MUTATION TW ORD 110136658 Pending
NCI E-230-2012-0-IL-67 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 IL DIV 286786 Issued
NCI E-053-2019-0-CN-10 GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCs) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES CN National Stage 202080026241.7 Pending
NCI E-174-2018-2-GB-14 TUMOR INFILTRATING LYMPHOCYTES AND METHODS OF THERAPY GB DIV 2113770.8 Issued
NCATS E-244-2014-0-EP-13 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof EP DIV 21181777.0 Pending
NIAID E-191-2018-0-HK-09 Improved Methods Of Manufacturing Peptide-Based Vaccines HK CN 62021039400.8 Pending
NCI E-211-2020-0-PCT-02 PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER PCT PCT PCT/US2021/052054 Expired
NIAID E-531-2013-2-IN-16 Epstein-Barr Virus Vaccines IN DIV 202118043476 Pending
NCATS E-133-2020-1-PCT-01 METHODS AND SYSTEMS FORMANAGING FLUID FLOW INCONTAINERS PCT PCT COMB PCT/US2021/051525 Expired
NCI E-174-2018-2-US-15 Tumor Infiltrating Lymphocytes and Methods of Therapy US CON 17/481,404 Pending
NCI E-084-2019-0-US-05 AUTOMATIC SYSTEM AND METHOD FOR TISSUE SECTIONING, STAINING, AND SCANNING US National Stage 17/440,368 Pending
NIAID E-081-2013-4-US-19 PREFUSION RSV F PROTEINS AND THEIR USE US CON 17/478,533 Pending
NCI E-171-2018-9-US-07 MODIFIED CELLS AND METHODS OF THERAPY US CON 17/478,615 Pending
NINDS E-102-2019-1-US-02 HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC
RESONANCE IMAGING OF CORTICAL LESIONS 		US National Stage 17/593,365 11921181 Issued PDF
NIDCR E-107-2022-1-CN-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) CN National Stage 202180077283.8 Pending
NIDCR E-107-2022-1-EP-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) EP National Stage 21790717.9 Pending
NIDCR E-107-2022-1-US-02 Treatment Methods Of Triphenyl Calcilytic Compounds US ORD 17/477,198 Pending
NCI E-036-2021-2-PCT-01 METHODS FOR TREATING INFECTIONS PCT PCT COMB PCT/US2021/050658 Expired
NHGRI E-167-2020-0-PCT-02 Novel Adeno-associated Viral (AAV) Vectors To Treat Hereditary Methylmalonic Acidemia (MMA) Caused By Methylmalonyl-coA Mutase (MMUT) Deficiency PCT PCT PCT/US2021/050699 Expired
NIDCR E-107-2022-1-EA-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) EA National Stage 202390918 Pending
NIDCR E-107-2022-1-PCT-03 Treatment Methods Of Triphenyl Calcilytic Compounds PCT PCT PCT/US2021/050677 Expired
NIDCR E-107-2022-1-KR-01 TRIPHENYL CALCILYTIC COMPOUNDS FOR THE TREATMENT OF AUTOSOMAL DOMINANT HYPOCALCEMIA TYPE 1 (ADH1) KR National Stage 10-2023-7012476 Pending